OGFR and pancreatic neoplasm: Second, OGFr has been characterized in human pancreatic cancer cells and surgical specimens by receptor binding [13,14], and shown to have at least a 10-fold greater affinity for OGFr than any other natural or synthetic opioid peptide (including those specific for μ, δ, or κ classical opioid receptors) [13].